JPMorgan Ultra Short Income ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.28 (market cap $42.37B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: JPMorgan Ultra Short Income ETF is the larger of the two by market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 46 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| JPST | ROIV | |
|---|---|---|
Market Cap | $42.37B | $25.09B |
Volume | 6,289,709 | 5,738,571 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $41.81 |
52-Week Low | $50.22 | $16.04 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $21.36B |
Signals from Pluang's Aura AI — not financial advice
JPST trades at $50.27, up 0.04% with a bearish technical signal from moving averages. The ETF shows neutral oscillators like RSI near 35, while recent news highlights institutional selling and mixed sentiment on its yield competitiveness. Dividend payments of $0.17 are scheduled through October 2026, but key financial ratios are unavailable for fundamental assessment.
Outlook remains cautious due to technical weakness and underperformance concerns cited by analysts. Risks include interest rate sensitivity and expense ratios, but demand for ultra-short income ETFs amid market volatility offers stability. Investors should weigh yield against peer comparisons and fee structures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →